Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Martinez, P.
  • Sundling, C.
  • O'Dell, S.
  • Mascola, J. R.
  • Wyatt, Richard
  • Hedestam, G. B. K.

publication date

  • March 2015

journal

  • Scientific Reports  Journal

abstract

  • Protein-based vaccines require adjuvants to achieve optimal responses. Toll-like receptor (TLR) 9 agonists were previously shown to improve responses to protein-based vaccines, such as the Hepatitis B virus vaccine formulated in alum. Here, we used CpG-C together with the clinically relevant saponin-based adjuvant AbISCO-100/Matrix-M (AbISCO), to assess if TLR9 co-stimulation would quantitatively or qualitatively modulate HIV-1 envelope glycoprotein (Env)-specific B and T cell responses in rhesus macaques. The macaques were inoculated with soluble Env trimers in AbISCO, with or without the addition of CpG-C, using an interval similar to the Hepatitis B virus vaccine. Following a comprehensive evaluation of antigen-specific responses in multiple immune compartments, we show that the Env-specific circulating IgG, memory B cells and plasma cells displayed similar kinetics and magnitude in the presence or absence of CpG-C and that there was no apparent difference between the two groups in the elicited HIV-1 neutralizing antibody titers or antigen-specific CD4+ T cell responses. Importantly, the control of SHIV viremia was significantly improved in animals from both Env-immunized groups relative to adjuvant alone controls, demonstrating the potential of AbISCO to act as a stand-alone adjuvant for Env-based vaccines.

subject areas

  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Neutralizing
  • Antibody Specificity
  • B-Lymphocytes
  • Cytokines
  • Disease Models, Animal
  • HIV Antibodies
  • HIV Infections
  • HIV-1
  • Humans
  • Immunity, Mucosal
  • Immunization
  • Immunoglobulin G
  • Immunologic Memory
  • Macaca mulatta
  • Oligodeoxyribonucleotides
  • Plasma Cells
  • Primates
  • Saponins
  • Simian Immunodeficiency Virus
  • T-Lymphocyte Subsets
  • Toll-Like Receptor 9
  • env Gene Products, Human Immunodeficiency Virus
scroll to property group menus

Identity

PubMed Central ID

  • PMC4356977

International Standard Serial Number (ISSN)

  • 2045-2322

Digital Object Identifier (DOI)

  • 10.1038/srep08925

PubMed ID

  • 25762407
scroll to property group menus

Additional Document Info

start page

  • 8925

volume

  • 5

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support